Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY, Denmark, Dec. 19, 2025 /PRNewswire/ -- Kongens Lyngby, Denmark, December 19, 2025 – The Board of Directors of Aquaporin A/S ("Aquaporin" or the "Company"), an innovative water technology company dedicated to rethinking water filtration with biotechnology, hereby updates on its strategic review and provides preliminary 2026 guidance and certain information on its mid- and long-term strategy.
Update on strategic review
In August 2025, Aquaporin announced its initiation of a strategic review to explore multiple opportunities to raise capital, including through equity and/or a strategic transaction or partnership. The Company's current financial position entails that additional capital is needed from the beginning of 2026 to fund the Company's operations and support Aquaporin's growth targets.
At an extraordinary general meeting held on December 1, 2025, the Company's shareholders approved to authorize the Board of Directors to issue new shares in either a rights issue or a directed issue without pre-emptive rights. Following a thorough strategic review process in which FIH Partners A/S has acted as financial adviser to the Company, and which includes constructive dialogues with a group of existing shareholders and potential new investors and partners, the Board of Directors has today resolved to carry out a rights issue aiming for gross proceeds of up to approximately DKK 78 million to provide a focused funding of the Company's short-term capital requirements towards second quarter 2027. The terms of the rights issue will be announced in a separate company announcement today. Should the rights issue not be completed or raise gross proceeds to the Company of significantly less than expected, there will be material uncertainty as to whether the Company can remain a going concern, and the Company may have to implement material changes to its business plan, including adjusting the pace of execution thereof, implementing measures to reduce costs, and/or seeking alternative opportunities to secure funding, including potentially in the form of partnerships or divestment of certain assets or business segments, or raise new equity or debt sooner than expected.
The Company will as part of its ongoing strategic review continue to explore multiple opportunities in parallel to raising equity capital to execute on its strategy and support stronger commercial development as well as to provide the Company with flexibility to explore and pursue strategic options for further funding until profitability in the mid-term.
Preliminary 2026 guidance
For the financial year 2026, Aquaporin expects to approximately double revenue compared to the revenue to be generated in ...
